← Human Trials & Peer-Reviewed Studies
Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenomectomy for Non-ACTH-Secreting Macroadenomas.
Plain-language guide to PMID 31225871 (2019): observational study of ACTH (Corticotropin) and Cosyntropin.
Key Facts
- PMID
- 31225871
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2019
- Study type
- Observational Study
- Authors
- Pofi R et al. (11 authors)
- DOI
- 10.1210/jc.2019-00406
What This Study Did, in Plain Language
What Was Tested
Researchers studied ACTH (Corticotropin) and Cosyntropin in this observational study publication.
To assess timing and predictors of HPA axis recovery after TSA.
Why It Was Studied
Secondary adrenal insufficiency is a potential complication of transsphenoidal adenomectomy (TSA).
Most centers test recovery of the hypothalamo-pituitary-adrenal (HPA) axis after TSA, but, to their knowledge, there are no data predicting likelihood of recovery or the frequency of later recovery of HPA function.
Who Took Part
PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.
Patients (N = 109) with short Synacthen test (SST) data before and at sequential time points after TSA.
How the Study Was Run
Single-center, retrospective analysis of consecutive pituitary surgeries performed between February 2015 and September 2018.
What Was Measured
Secondary adrenal insufficiency is a potential complication of transsphenoidal adenomectomy (TSA).
Most centers test recovery of the hypothalamo-pituitary-adrenal (HPA) axis after TSA, but, to their knowledge, there are no data predicting likelihood of recovery or the frequency of later recovery of HPA function.
Topics PubMed links to this paper include Adenoma, Adrenal Insufficiency, Hydrocortisone, Hypothalamo-Hypophyseal System, Neurosurgical Procedures, Pituitary Neoplasms and Pituitary-Adrenal System.
What This Means in Plain Language
This is an observational study of ACTH (Corticotropin) and Cosyntropin.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the ACTH (Corticotropin) compound page and the Cosyntropin compound page, all human trials.
Our Notes on the Compounds
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
Cosyntropin: A synthetic 24-amino-acid fragment of ACTH (also tetracosactide, Synacthen) used mainly in the adrenal stimulation test.
Alpha-MSH: A 13-amino-acid hormone that drives skin pigmentation and calms inflammation; afamelanotide (Melanotan I) is an analog.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.